Skip to main content

Conference Correspondent 

Targeted alpha-particle therapy is in development for targeted radionuclide therapy of NETs, employing alpha decay to treat diseased tissue at close proximity. Read More ›

Telotristat ethyl is safe and effective in reducing intractable diarrhea in patients with carcinoid syndrome. Read More ›

An expert working group developed specific ideas for future research programs in NETs, as well as ways to improve access to NET clinical trials. Read More ›

The current study found no clear evidence linking eltrombopag treatment and risk for cataract development/progression in patients with chronic immune thrombocytopenia (ITP). Read More ›

The current post-hoc subanalysis of a phase 4 open-label study concluded that the effects on platelet counts after eltrombopag treatment for >2 years was comparable between the persistent immune thrombocytopenia (ITP) and the chronic ITP cohorts, with similar safety profiles. Read More ›

These study results showed that heavily pretreated patients with persistent/chronic immune thrombocytopenia (ITP) who achieved a stable response with fostamatinib therapy maintained their responses for ≥12 months. Read More ›

Results of this randomized, placebo-controlled phase 3 trial showed that avatrombopag was superior to placebo in terms of the cumulative number of weeks with a platelet response, platelet response at day 8, and durability of platelet response in patients with refractory chronic immune thrombocytopenia (ITP). Read More ›

This open-label study reported that the majority of children with immune thrombocytopenia (ITP) who received open-label romiplostim for ≥6 months achieved a platelet response, with median platelet counts >50 × 109/L from week 12 onward and no new safety signals observed during the study period. Read More ›

Questions About Treating Patients Using a CDK4/6 Inhibitor
Dr Matthew Goetz addresses common questions that arise when patients with HER+ metastatic breast cancer have progressed on a CDK4/6 inhibitor plus an aromatase inhibitor. Read More ›

The Use of Chemotherapy in the Metastatic Setting
Dr Matthew Goetz believes that, as more mature data come into existence, the demonstration of a survival advantage will guide more patients with metastatic breast cancer to try CDK4/6 inhibitors plus aromatase inhibitors instead of chemotherapy. Read More ›

Page 14 of 28